"The Second Time is Sweeter After All". - Wikidata - wikimedia - TriplyDB

"The Second Time is Sweeter After All".

"The Second Time is Sweeter After All".

http://www.wikidata.org/entity/Q50919950

about

"The Second Time is Sweeter After All".

http://www.wikidata.org/entity/Q50919950

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

"The Second Time is Sweeter After All".

@en

"The Second Time is Sweeter After All".

@nl

type

label

"The Second Time is Sweeter After All".

@en

"The Second Time is Sweeter After All".

@nl

prefLabel

"The Second Time is Sweeter After All".

@en

"The Second Time is Sweeter After All".

@nl

P1433

Q50919950-7228DFB8-1602-48A9-B0CC-136CAE7FFF88

P1476

Q50919950-F4CBDC18-C0EE-4168-9022-C7472D66E20F

P2860

Q50919950-06168085-5799-43E7-B994-213DC041CC70

Q50919950-1C150DE1-46E0-40CF-8FAE-FCD691787EAA

Q50919950-2F0917F4-A235-4182-B96F-E00B242FF4ED

Q50919950-428D1284-FF27-40D7-BC00-D658E607B879

Q50919950-67579E26-F43E-4DBE-8E52-D03655BDC2BE

Q50919950-6B61442F-B97A-48FB-A531-ECD7FA43803D

Q50919950-7119BFFC-9848-47B2-A310-C7EB9FDA220D

Q50919950-85DD2BD0-56E6-4695-9EBB-75D62B96E9D6

Q50919950-A6C5DB74-FA9E-4F63-810F-9CE663D78D91

Q50919950-B5E9207A-8A06-4EA1-921A-92AAE5F60D55

P304

Q50919950-19814174-1818-4C48-B603-576AA8D60963

P31

Q50919950-3b282573-cfa9-479b-a2ee-5512d17ed767

Q50919950-D4C47ACC-F5B9-4130-9FC2-E3BBB343504F

P356

Q50919950-7738ECC4-FDD1-49EE-9306-593838B4DA9C

P407

Q50919950-0AC50B51-4125-4A9B-8973-B71DA6C84EB1

P433

Q50919950-718AD3C8-9EC6-4FA2-AF06-C6C6C9953B49

P478

Q50919950-4170945D-F8F3-453F-BFE9-A578CFB0A156

P50

Q50919950-4AA0C0AB-6AE7-4B7D-A612-229DD1DE43B7

P577

Q50919950-4D3CD2DB-2BBF-42A5-84B3-135534CE973B

P698

Q50919950-35A555CA-2349-49FE-ABD5-3043DAFCB1DA

P356

P1433

British Journal of Haematology

P1476

"The Second Time is Sweeter After All".

@en

P2860

Why most published research findings are false

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

An historic perspective of proteasome inhibition.

Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.

Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

P304

511-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14503

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28145575

http://www.w3.org/2001/XMLSchema#string